NASDAQ:CBIO
Crescent Biopharma, Inc.
Crescent Biopharma, Inc.'s revenue was $10.8M in fiscal 2025. Free cash flow was −$72.5M, −668.1% of revenue.Summary generated from Crescent Biopharma, Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$10.8M
Revenue growthn/a
Revenue, 5-yr CAGR+1.3%
Gross marginn/a
Operating margin−1407.5%
Net margin−1419.6%
ROICn/a
Return on equity−164.2%
Debt / equityn/a
Free cash flow−$72.5M
FCF margin−668.1%
Share count changen/a
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 | 0 | 0 | n/a | 11 |
| Operating income | −63 | −47 | −39 | −40 | −153 |
| Net income | −63 | −47 | −37 | −38 | −154 |
| Free cash flow | −58 | −47 | −35 | −31 | −72 |
Recent filings
- 4Insider transaction report
Sep 18, 2026 - 4Insider transaction report
Sep 18, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Jul 30, 2026 - 8-KResults of operations and financial condition
Jul 30, 2026 - 8-KOther events
Jul 15, 2026 - 8-KResults of operations and financial condition
Jul 14, 2026 - 10-Q/AAmended quarterly report for the period ended Mar 31, 2026
Jun 22, 2026 - 8-KResults of a shareholder vote
Jun 3, 2026